Skip to main content
. 2012 Apr 11;21(17):3125–3135. doi: 10.1089/scd.2012.0096

FIG. 2.

FIG. 2.

MSCs and BMCs prevent from developing late allograft dysfunction. The animals treated with MSCs or BMCs did not increase the proteinuria levels, reaching significant differences at 20 and 24 weeks when compared with NT animals (P<0.05). In parallel, serum creatinine levels were nonpathologically maintained in both cell-injected groups (*P<0.05 NT vs. BMC, **P<0.001 vs. MSC, ***P<0.001 NT vs. MSC and BMC). NT, no-therapy.